# A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Source: https://onco.cc/trials/nct02972840/  
OnCo record `nct02972840` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Acalabrutinib, Bendamustine and Rituximab in mantle cell lymphoma, run by Acerta Pharma BV, active and no longer recruiting.

## Summary

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL is a phase 3 interventional study registered as NCT02972840 by Acerta Pharma BV, with 635 participants enrolled, started 2017-04-05 and due to reach its primary completion in 2027-02-15. Interventions recorded: Acalabrutinib, Bendamustine, Rituximab and Placebo.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Also known as: ECHO; Acalabrutinib with bendamustine and rituximab in untreated mantle cell lymphoma
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02972840
- Phase: 3
- Setting: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
- Sponsor: Acerta Pharma BV
- Enrolled: 635
- Result: Median progression-free survival 66.4 against 49.6 months (hazard ratio 0.73, p = 0.0160), with no significant overall survival difference (hazard ratio 0.86, p = 0.27).

## Sources

- ClinicalTrials.gov NCT02972840: https://clinicaltrials.gov/study/NCT02972840

## Connected records

- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)
- key papers: [Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma](https://onco.cc/key-papers/paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025/), [Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma](https://onco.cc/key-papers/paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022/)
- trials: [ENRICH](https://onco.cc/trials/enrich/), [SHINE](https://onco.cc/trials/shine/)
- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [BTK (Bruton tyrosine kinase)](https://onco.cc/targets/btk/), [CCND1](https://onco.cc/targets/ccnd1/), [CD20](https://onco.cc/targets/cd20/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Bendamustine](https://onco.cc/drugs/bendamustine/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- pathways: [B-cell receptor / BTK signalling (to NF-κB)](https://onco.cc/pathways/bcr-signalling/)

---
JSON: https://onco.cc/api/v1/entities/nct02972840.json